Rezolute (RZLT) Stock Forecast & Price Target

Rezolute is well-positioned for success with its lead candidates RZ358 and RZ402 targeting unmet medical needs in rare diseases and DME, respectively. The company's strong pipeline, positive interim results, and partnerships with medical communities and patient groups suggest a high likelihood of successful product development and regulatory approvals. Along with the company's conservative end of $400,000 to $600,000 per patient range for annual list price for cHI, the high probability of positive readouts and potential for additional 50+% upside to the $11 PT makes Rezolute a promising investment.

Rezolute is facing potential delays in the approval process due to their inability to meet FDA's guidelines, which could negatively impact their timelines and revenue projections. Additionally, the company is highly dependent on the success of their experimental drug, ersodetug, in both the congenital and tumor hyperinsulinism markets, and any setbacks or failures could greatly impact their financials. With a current market cap of ~$400M and potential for a PRV worth over $150M, there is a significant amount of speculative value baked into the stock, making it a risky investment choice.